ABSTRACT
PURPOSE: MRI is essential in the management of brain tumours. However, long waiting times reduce patient accessibility. Reducing acquisition time could improve access but at the cost of spatial resolution and diagnostic quality. A commercially available artificial intelligence (AI) solution, SubtleMR™, can increase the resolution of acquired images. The objective of this prospective study was to evaluate the impact of this algorithm that halves the acquisition time on the detectability of brain lesions in radiology and radiotherapy. MATERIAL AND METHODS: The T1/T2 MRI of 33 patients with brain metastases or meningiomas were analysed. Images acquired quickly have a matrix divided by two which halves the acquisition time. The visual quality and lesion detectability of the AI images were evaluated by radiologists and radiation oncologist as well as pixel intensity and lesions size. RESULTS: The subjective quality of the image is lower for the AI images compared to the reference images. However, the analysis of lesion detectability shows a specificity of 1 and a sensitivity of 0.92 and 0.77 for radiology and radiotherapy respectively. Undetected lesions on the IA image are lesions with a diameter less than 4mm and statistically low average gadolinium-enhancement contrast. CONCLUSION: It is possible to reduce MRI acquisition times by half using the commercial algorithm to restore the characteristics of the image and obtain good specificity and sensitivity for lesions with a diameter greater than 4mm.
Subject(s)
Algorithms , Artificial Intelligence , Brain Neoplasms , Magnetic Resonance Imaging , Meningioma , Humans , Magnetic Resonance Imaging/methods , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/radiotherapy , Prospective Studies , Meningioma/diagnostic imaging , Meningioma/radiotherapy , Meningeal Neoplasms/diagnostic imaging , Meningeal Neoplasms/radiotherapy , Female , Male , Radiation Oncology/methods , Middle Aged , Aged , Time Factors , Sensitivity and Specificity , Adult , Radiology Department, HospitalABSTRACT
Le carcinome hépatocellulaire (CHC), est une affection fortement associée aux maladies chroniques du foie en particulier la cirrhose. Son incidence et sa mortalité augmentent avec une grande disparité géographique en rapport avec la répartition de ses étiologies. La morbidité augmente, bien qu'on note une meilleure prise en charge des autres complications de la cirrhose ; la mortalité reste élevée en raison du diagnostic souvent tardif du CHC. La chirurgie demeure le seul traitement curatif validé. De toutes les procédures chirurgicales, la transplantation est de loin celle qui offre la possibilité de traiter en un temps le CHC et son étiologie. Dans notre contexte, de pays en développement avec des infrastructures et du personnel qualifié limités, la transplantation est inaccessible. Pour cette raison, la résection partielle du foie reste l'approche la plus adaptée dans nos structures en Afrique. A partir d'une observation, nous discutons de sa faisabilité, de ses indications, de son efficacité et du devenir du foie restant